Clinical trial
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary…
NCT00185315 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00185315 |
|---|---|
| Title | Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension |
| Official title | Open-label, Uncontrolled, Long-term Surveillance Study of Iloprost Aerosol Inhalation Therapy in the Treatment of Patients With Primary or Secondary Pulmonary Hypertension. Follow-up Program for Patients Who Completed 12 Weeks in Study ME97218/300180. |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension, Pulmonary |
| Intervention type | Drug |
| Interventions | Ventavis (Iloprost, BAYQ6256) |
| Enrollment | 71 |
| Start date | Feb 1, 2000 |
| Completion | Aug 1, 2005 |
| First posted | Sep 16, 2005 |
| Last update posted | Apr 20, 2010 |
| Countries | Belgium, France, Italy, Netherlands, Poland, Portugal, Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: